https://www.selleckchem.com/pr....oducts/pembrolizumab
ients (p=0.015 when comparing obese vs normal weight subjects), but disproved differences in mortality (p0.05 for all comparisons). Irrespective of BMI class, TAVI is associated with favorable outcomes in surgical high-risk risk patients, with the notable exclusion of permanent pacemaker implantation, which is significantly more common in obese subjects. Irrespective of BMI class, TAVI is associated with favorable outcomes in surgical high-risk risk patients, with the notable exclusion of permanent pacemaker implantation, whic
Like
Comment
Share
